BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 23870857)

  • 1. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
    Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
    Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines.
    Wehner P; Lagios MD; Silverstein MJ
    Ann Surg Oncol; 2013 Oct; 20(10):3175-9. PubMed ID: 23975306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of vacuole membrane protein 1 and its prognostic value in invasive ductal carcinoma of the breast].
    Liu F; Niu Y; Liu N; Zhang W; Wang SL; Liu H; Zhang TX
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):86-9. PubMed ID: 23710913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI.
    Vicini F; Shah C; Ben Wilkinson J; Keisch M; Beitsch P; Lyden M
    Ann Surg Oncol; 2013 Apr; 20(4):1275-81. PubMed ID: 23054123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component.
    Lampejo OT; Barnes DM; Smith P; Millis RR
    Semin Diagn Pathol; 1994 Aug; 11(3):215-22. PubMed ID: 7831533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
    Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
    Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
    Boland GP; Chan KC; Knox WF; Roberts SA; Bundred NJ
    Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas.
    de Mascarel I; MacGrogan G; Mathoulin-Pélissier S; Soubeyran I; Picot V; Coindre JM
    Cancer; 2002 Apr; 94(8):2134-42. PubMed ID: 12001109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.